The average price of new drugs has risen by 35% in 2023 compared to the previous year in the US, with gene therapies becoming the most expensive treatments due to their curative potential and rarity of the conditions they treat. Among these are Orchard Therapeutics’ Lenmeldy for metachromatic leukodystrophy ($4.25 million), uniQure’s Hemgenix for hemophilia B ($3.5 million), Sarepta Therapeutics’ Elevidys for Duchenne muscular dystrophy ($3.2 million), and Vertex Pharmaceuticals’ Casgevy for sickle cell disease and beta-thalassemia ($2.2 million).
Ontario Divisional Court Rules Forensic Reports as Non-Privileged
Hello folks! I was having a peruse around the cyber world when I spotted an interesting conversation on Infosec Exchange – a spot of legal
